<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958282</url>
  </required_header>
  <id_info>
    <org_study_id>0812M54801</org_study_id>
    <secondary_id>DA023548</secondary_id>
    <nct_id>NCT00958282</nct_id>
  </id_info>
  <brief_title>Treatment of Cocaine Dependence With Lisdexamfetamine</brief_title>
  <official_title>Lisdexamfetamine Treatment for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a 2-group double-blind placebo-controlled outpatient study investigating
      lisdexamfetamine for treatment of cocaine dependence. The investigators plan to enroll 100
      subjects in a 14-week trial. The primary objectives will determine changes in cocaine use and
      secondary objectives will be cocaine craving and impulsivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 2-group, double-blind, placebo-controlled, 14-week study (N=100) will investigate the
      efficacy of cognitive behavioral therapy plus lisdexamfetamine vs. placebo to treat cocaine
      dependence. We hypothesize that lisdexamfetamine will reduce cocaine use (primary outcome),
      as well as cocaine craving and impulsivity (secondary outcomes) vs. placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine-positive Urine Results</measure>
    <time_frame>14 Weeks</time_frame>
    <description>At each visit, subjects provided urine samples, which were analyzed for benzoylecgonine (BE; a cocaine metabolite). BE was assessed semi-quantitatively using the PROFILE® -V MEDTOXScan® Drugs of Abuse Test System, with cocaine positive tests equaling or exceeding 150 ng/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Craving</measure>
    <time_frame>14 Weeks</time_frame>
    <description>On a weekly basis, patients completed measures of cocaine craving using the Minnesota Cocaine Craving Scale.
The Minnesota Cocaine Craving Scale is a self report questionnaire and ranges from 0 to 100, 0 being &quot;very little&quot; to 100 being &quot;very much&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>lisdexamfetamine/Behavior Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lisdexamfetamine 70mg/day plus Behavior Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator once per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lisdexamfetamine/Behavior Therapy</intervention_name>
    <arm_group_label>lisdexamfetamine/Behavior Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible participants must:

               1. Be treatment-seeking males or females between 18 and 65 years-of-age;

               2. Understand the study procedures and provide written informed consent;

               3. Be judged by the examining physician to be in generally good health with the
                  exception of health problems related to acute drug use;

               4. Meet DSM-IV criteria for cocaine-dependence.

        Exclusion Criteria:

          -  Exclusion criteria include:

               1. DSM-IV diagnoses for current psychotic disorders, mood disorders (except
                  substance-induced depression), anxiety disorders, ADHD, and other current
                  substance dependence (except marijuana and nicotine dependence); subjects may not
                  have physiological dependence upon alcohol requiring medical detoxification;

               2. Current use of any prescription medications;

               3. Females currently pregnant or nursing;

               4. Current elevation of liver enzyme levels above twice normal limits;

               5. Existing cardiovascular disease as determined by physician, EKG evaluation;

               6. History of significant acute or chronic physical illness precluding
                  participation;

               7. History of hyperthyroidism, glaucoma, or seizures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Mooney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ambulatory Research Center/Fairview University Psychiatry Dept</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <results_first_submitted>June 11, 2015</results_first_submitted>
  <results_first_submitted_qc>August 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 17, 2015</results_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>treatment</keyword>
  <keyword>lisdexamfetamine</keyword>
  <keyword>dependence</keyword>
  <keyword>addiction</keyword>
  <keyword>crack</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lisdexamfetamine</title>
          <description>lisdexamfetamine 70mg/day
lisdexamfetamine
cognitive behavioral therapy</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo Comparator once per day
placebo
cognitive behavioral therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lisdexamfetamine</title>
          <description>lisdexamfetamine 70mg/day
lisdexamfetamine
cognitive behavioral therapy</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo Comparator once per day
placebo
cognitive behavioral therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.1" spread="5.9"/>
                    <measurement group_id="B2" value="46.4" spread="10"/>
                    <measurement group_id="B3" value="46.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine-positive Urine Results</title>
        <description>At each visit, subjects provided urine samples, which were analyzed for benzoylecgonine (BE; a cocaine metabolite). BE was assessed semi-quantitatively using the PROFILE® -V MEDTOXScan® Drugs of Abuse Test System, with cocaine positive tests equaling or exceeding 150 ng/mL.</description>
        <time_frame>14 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lisdexamfetamine</title>
            <description>lisdexamfetamine 70mg/day
lisdexamfetamine
cognitive behavioral therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Comparator once per day
placebo
cognitive behavioral therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine-positive Urine Results</title>
          <description>At each visit, subjects provided urine samples, which were analyzed for benzoylecgonine (BE; a cocaine metabolite). BE was assessed semi-quantitatively using the PROFILE® -V MEDTOXScan® Drugs of Abuse Test System, with cocaine positive tests equaling or exceeding 150 ng/mL.</description>
          <units>percentage of BE urine tests</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" spread=".5"/>
                    <measurement group_id="O2" value="92.4" spread=".5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Craving</title>
        <description>On a weekly basis, patients completed measures of cocaine craving using the Minnesota Cocaine Craving Scale.
The Minnesota Cocaine Craving Scale is a self report questionnaire and ranges from 0 to 100, 0 being &quot;very little&quot; to 100 being &quot;very much&quot;.</description>
        <time_frame>14 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lisdexamfetamine</title>
            <description>lisdexamfetamine 70mg/day
lisdexamfetamine
cognitive behavioral therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Comparator once per day
placebo
cognitive behavioral therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Craving</title>
          <description>On a weekly basis, patients completed measures of cocaine craving using the Minnesota Cocaine Craving Scale.
The Minnesota Cocaine Craving Scale is a self report questionnaire and ranges from 0 to 100, 0 being &quot;very little&quot; to 100 being &quot;very much&quot;.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="3.30"/>
                    <measurement group_id="O2" value="28.7" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lisdexamfetamine/Behavior Therapy</title>
          <description>lisdexamfetamine 70mg/day plus Behavior Therapy
lisdexamfetamine/Behavior Therapy</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo Comparator once per day
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <description>A patient was hospitalized for chest pain and diagnosed with angina that was possibly related to the study drug. He did not continue in the study. He was assigned to the LDX condition.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosis</sub_title>
                <description>A subject was hospitalized with psychosis (assigned to the placebo condition). She had apparently binged on cocaine prior to her psychotic episode. In addition she failed to reveal to study staff that she was diagnosed with schizoaffective disorder.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marc Mooney</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>6129916875</phone>
      <email>moon0078@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

